Basel, Switzerland-based biotechnology firm Speedel has successfully completed a convertible bond issue of roughly 55.5 million Swiss francs ($42.0 million) before underwriting commissions and expenses. According to the firm, demand was very strong and the conversion premium was therefore increased to 35.9% from the indicative range of 27% to 33%. Bank Vontobel AG and Bank Rud, Blass & Cie AG acted as lead manager and co-lead manager, respectively. The final terms set on the basis of the book-building process include a reference share price of 166.3 francs, a conversion price of 226 francs and a 1,000 francs denomination per bond. The payment date is January 24.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze